Google
Nurix Therapeutics Stock Sees RS Rating Jump To 82
Nurix Therapeutics stock now meets that criteria, with a jump from 77 to 82 Wednesday. IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matches up against that of all other stocks. Is Nurix Therapeutics Stock A Buy?
Continue Reading
